FierceBiotech11d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
BioPharma Dive11d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical ...
pharmaphorum1d
Regenxbio expands MPS I gene therapy trial after first look at data
Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...
Hosted on MSN6mon
Umbilical cord stem cells donated in 2008 transform life of five-year-old boy with rare genetic disorder
He’s a clever boy with an amazing bond with his big sister.” Gunner has mucopolysaccharidosis type I hurler syndrome, a rare inherited condition that prevents the breakdown of certain sugars ...
BioWorld9d
Regenxbio, Nippon Shinyaku in $810M deal for Hunter and Hurler gene therapies
In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...
Regenxbio, Nippon Shinyaku enter commercialization pact for RGX-121
Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of ...